Cardio ThinkLab

STRONG-HF study highlighting benefits of treatment optimisation


Primary outcomes

Heart failure patients currently have high rates of readmission and mortality after discharge1-4


Sign up for the Master Pack to unlock exclusive insights from Prof Mebazaa, the principal investigator of the STRONG-HF study.

The burden of heart failure

64.3 million adults suffer from heart failure1

1 in 4 patients are re-admitted within 30 days of discharge1,2,3

About 1 in 2 patients are re-admitted within 6 months4

More than 1 in 2 patients die within 5 years with survival rates worse than:

  • colon cancer
  • breast cancer
  • prostate cancer1

What are the challenges of post-discharge management?

Majority of heart failure patients are not closely monitored or treated with optimal doses of GDMT5-11 after acute heart failure admission.

ACEis, ARBs, MRAs and beta-blockers showed to improve survival rates.12

Factors influencing limited adherence to GDMT (Guideline Directed Medical Therapy).13

  1. Lack of awareness
  2. Focus on treating symptoms
  3. Fear of adverse effects
  1. Age
  2. Frailty and sensitivity
  3. Intolerance and contraindications
  1. High costs
  2. Limited access

STRONG-HF primary outcomes show significant reduction of all cause death or acute heart failure readmissions

Study Design

patients enrolled
out of planned 1800
years old

Monitoring board of the study recommended to terminate the study early as it was considered unethical to continue with usual care.

*ACEi/ARB, ARNi, BB, or MRA; **NT-proBNP criteria for persistent congestion ACEi, angiotensin-converting enzyme inhibitors; AHF, acute heart failure; ARB, angiotensin receptor blockers; BB, beta blockers; GDMT, guideline-directed medical therapy; HF, heart failure; MRA, mineralocorticoid receptor antagonists; NT-proBNP, N-terminal pro b-type natriuretic peptide

Measuring NT-proBNP biomarker levels is an integral part of the treatment strategy in STRONG-HF.


The high intensity care group: 34% relative and 8.1% absolute risk reduction (ARR) in the combination of death or heart failure readmission.14

CV (cardiovascular) death
26% lower

HF readmission
44% lower

All-cause death
16% lower
STRONG-HF study results demonstrated clear benefits for acute heart failure patients by adapting the strategy of care.

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi